A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration

Aim The current accepted standard treatment for neovascular age-related macular degeneration (AMD) consists of antivascular endothelial growth factor agents including ranibizumab and bevacizumab. The aim of the study was to examine whether bevacizumab is inferior to ranibizumab with respect to maint...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of ophthalmology 2013-03, Vol.97 (3), p.266-271
Hauptverfasser:	Krebs, Ilse, Schmetterer, Leopold, Boltz, Agnes, Told, Reinhard, Vécsei-Marlovits, Veronika, Egger, Stefan, Schönherr, Ulrich, Haas, Anton, Ansari-Shahrezaei, Siamak, Binder, Susanne
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Bevacizumab Diabetic retinopathy Dose-Response Relationship, Drug Female Follow-Up Studies Heart attacks Hospitals Humans Intravitreal Injections Macula Macular degeneration Macular Degeneration - drug therapy Macular Degeneration - pathology Macular Degeneration - physiopathology Male Myopia Neovascularisation Ophthalmology Photodynamic therapy Prospective Studies Ranibizumab Retina Retinal Neovascularization - drug therapy Retinal Neovascularization - pathology Retinal Neovascularization - physiopathology Studies Tomography, Optical Coherence Treatment Outcome Treatment Surgery Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!